Mitchell de Long
Corporate Officer/Principal at AERIE PHARMACEUTICALS, INC.
Mitchell de Long active positions
| Companies | Position | Start | End |
|---|---|---|---|
| AERIE PHARMACEUTICALS, INC. | Corporate Officer/Principal | 2004-12-31 | - |
Career history of Mitchell de Long
Former positions of Mitchell de Long
| Companies | Position | Start | End |
|---|---|---|---|
| PROCTER & GAMBLE COMPANY | Chief Tech/Sci/R&D Officer | - | - |
Training of Mitchell de Long
| Stanford University | Doctorate Degree |
Statistics
International
| United States | 4 |
Operational
| Doctorate Degree | 1 |
| Chief Tech/Sci/R&D Officer | 1 |
| Corporate Officer/Principal | 1 |
Sectoral
| Consumer Services | 2 |
| Consumer Non-Durables | 2 |
| Health Technology | 2 |
Positions held
Active
Inactive
Listed companies
Private companies
Linked companies
| Listed companies | 1 |
|---|---|
| PROCTER & GAMBLE COMPANY | Consumer Non-Durables |
| Private companies | 1 |
|---|---|
Aerie Pharmaceuticals, Inc.
 Aerie Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Aerie Pharmaceuticals, Inc. engages in the discovery, development, and commercialization of therapies for the treatment of patients with open-angle glaucoma, retinal diseases and other diseases of the eye. Its products include Rhopressa, Roclatan, AR-13503, and AR-1105. The company was founded by David L. Epstein, Casey C. Kopczynski, Thomas J. van Haarlem, and Eric J. Toone on January 1, 2005 and is headquartered in Durham, NCForth Worth, TX. | Health Technology |
- Stock Market
- Insiders
- Mitchell de Long
- Experience
